Amphastar Pharmaceuticals
AMPH
218 hedge funds and large institutions have $1.13B invested in Amphastar Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 76 increasing their positions, 82 reducing their positions, and 26 closing their positions.
285% more call options, than puts
Call options by funds: $2.23M | Put options by funds: $581K
48% more capital invested
Capital invested by funds: $764M → $1.13B (+$368M)
23% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 26
2.76% more ownership
Funds ownership: 60.3% → 63.06% (+2.8%)
2% more funds holding
Funds holding: 213 → 218 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 82
Top Buyers
| 1 |
GIP
Granite Investment Partners
El Segundo,
California
|
+$17.6M |
| 2 |
Neuberger Berman Group
New York
|
+$14.1M |
| 3 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$10.2M |
| 4 |
Millennium Management
New York
|
+$8.07M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$7.4M |
Top Sellers
| 1 |
BlackRock
New York
|
-$15.5M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.5M |
| 3 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$6.47M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$3.01M |
| 5 |
Morgan Stanley
New York
|
-$2.72M |
AMPH Hedge Fund Activity: Q1 2023 in Review
218 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q1 2023, worth a combined $1.13B — up 48% from $764M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new AMPH positions and 26 closed out — a net gain of 6 holders — while 76 added to existing stakes and 82 trimmed.
The largest buyer was Granite Investment Partners, opening a new position worth an estimated $17.6M. The largest seller was BlackRock, cutting an estimated $15.5M.
- 218 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q1 2023, up from 213 in Q4 2022.
- Funds reported $1.13B of Amphastar Pharmaceuticals stock for Q1 2023, up 48% quarter-over-quarter.
- 32 funds opened new Amphastar Pharmaceuticals positions in Q1 2023 and 26 closed out, a net change of +6 holders.
- The largest Amphastar Pharmaceuticals buyer in Q1 2023 was Granite Investment Partners, an estimated $17.6M added.
- The largest Amphastar Pharmaceuticals seller in Q1 2023 was BlackRock, an estimated $15.5M sold.
Based on aggregated 13F filings for Q1 2023.